Analysts forecast that Impax Laboratories Inc (NASDAQ:IPXL) will post earnings per share (EPS) of $0.12 for the current quarter, Zacks reports. Five analysts have made estimates for Impax Laboratories’ earnings. The lowest EPS estimate is $0.10 and the highest is $0.13. Impax Laboratories posted earnings per share of $0.16 during the same quarter last year, which would indicate a negative year over year growth rate of 25%. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 7th.
On average, analysts expect that Impax Laboratories will report full-year earnings of $0.64 per share for the current financial year, with EPS estimates ranging from $0.60 to $0.65. For the next financial year, analysts forecast that the business will report earnings of $1.02 per share, with EPS estimates ranging from $0.71 to $1.15. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Impax Laboratories.
Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. The firm had revenue of $206.40 million for the quarter, compared to analysts’ expectations of $208.38 million. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. The business’s revenue was down 9.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.37 EPS.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IPXL. Swiss National Bank boosted its stake in shares of Impax Laboratories by 15.3% during the second quarter. Swiss National Bank now owns 116,900 shares of the specialty pharmaceutical company’s stock valued at $1,882,000 after purchasing an additional 15,500 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Impax Laboratories by 7.5% during the second quarter. Teachers Advisors LLC now owns 131,944 shares of the specialty pharmaceutical company’s stock valued at $2,124,000 after purchasing an additional 9,159 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in Impax Laboratories by 1.0% during the second quarter. TIAA CREF Investment Management LLC now owns 238,473 shares of the specialty pharmaceutical company’s stock valued at $3,839,000 after acquiring an additional 2,463 shares during the last quarter. Pinebridge Investments L.P. lifted its position in Impax Laboratories by 1,101.2% during the second quarter. Pinebridge Investments L.P. now owns 115,560 shares of the specialty pharmaceutical company’s stock valued at $1,860,000 after acquiring an additional 105,940 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Impax Laboratories by 0.8% during the second quarter. Northern Trust Corp now owns 943,704 shares of the specialty pharmaceutical company’s stock valued at $15,195,000 after acquiring an additional 7,913 shares during the last quarter. Hedge funds and other institutional investors own 90.48% of the company’s stock.
Impax Laboratories (NASDAQ IPXL) traded down $0.40 during trading on Monday, reaching $20.15. 937,400 shares of the company were exchanged, compared to its average volume of 1,012,300. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32. Impax Laboratories has a 12 month low of $7.75 and a 12 month high of $25.70. The stock has a market cap of $1,490.00, a price-to-earnings ratio of -3.22, a P/E/G ratio of 1.06 and a beta of 0.94.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.